KW 3902
KW 3902 structure
|
Common Name | KW 3902 | ||
|---|---|---|---|---|
| CAS Number | 136199-02-5 | Molecular Weight | 356.46200 | |
| Density | 1.262g/cm3 | Boiling Point | 578ºC at 760mmHg | |
| Molecular Formula | C20H28N4O2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 303.4ºC | |
Use of KW 3902Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment.Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450)[1].Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases[2]. |
| Name | Rolofylline |
|---|---|
| Synonym | More Synonyms |
| Description | Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment.Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450)[1].Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases[2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.262g/cm3 |
|---|---|
| Boiling Point | 578ºC at 760mmHg |
| Molecular Formula | C20H28N4O2 |
| Molecular Weight | 356.46200 |
| Flash Point | 303.4ºC |
| Exact Mass | 356.22100 |
| PSA | 72.68000 |
| LogP | 2.78400 |
| Vapour Pressure | 2.33E-13mmHg at 25°C |
| Index of Refraction | 1.605 |
| Hazard Statements | H413 |
|---|---|
| RIDADR | NONH for all modes of transport |
|
~99%
KW 3902 CAS#:136199-02-5 |
| Literature: Kyowa Hakko Kogyo Co., Ltd. Patent: US5290782 A1, 1994 ; US 5290782 A |
|
~%
KW 3902 CAS#:136199-02-5 |
| Literature: Synthesis, , # 7 p. 1123 - 1126 |
|
~%
KW 3902 CAS#:136199-02-5 |
| Literature: Journal of Medicinal Chemistry, , vol. 35, # 5 p. 924 - 930 |
|
~%
KW 3902 CAS#:136199-02-5 |
| Literature: Journal of Medicinal Chemistry, , vol. 35, # 5 p. 924 - 930 |
|
~%
KW 3902 CAS#:136199-02-5 |
| Literature: Synthesis, , # 7 p. 1123 - 1126 |
|
The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.
Am. J. Ther. 17(1) , 53-60, (2010) Rolofylline is a potent, selective adenosine A1 receptor antagonist that was under development for the treatment of patients with acute decompensated heart failure and renal function impairment. This ... |
|
|
The disconnect between phase II and phase III trials of drugs for heart failure.
Nat. Rev. Cardiol. 10(2) , 85-97, (2013) Hospitalization for heart failure (HF) is a clinical entity associated with high postdischarge morbidity and mortality, yet few therapies are available to improve outcomes in patients with this condit... |
|
|
Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.
J. Card. Fail. 16(1) , 25-35, (2010) Current treatment for acute decompensated heart failure (ADHF) is associated with incomplete resolution of symptoms and signs, recurrent symptoms of heart failure in-hospital and after discharge and h... |
| KW 3902 |
| MK-7418 |
| 1,3-Dnax |